Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.
August 02, 2022
Biotechnology company OrcaBio announces OHSU is one of six sites in a new Phase 3 clinical trial designed to study the efficacy of their Orca-T therapy in patients with acute myeloid leukemia, acute lymphocytic leukemia and high-risk myelodysplastic syndromes.